Tag: attention deficit hyperactivity disorder adhd therapeutics market segmentation

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Sector?

The market size for therapeutics of Attention Deficit Hyperactivity Disorder (ADHD) has been expanding positively over recent years. There is expected growth from $13.21 billion in 2024 to $13.97 billion in 2025, reflecting a 5.7% Compound Annual Growth Rate (CAGR). The market’s growth in the past years can be associated with factors such as increased awareness in diagnostics and screening programs, a surge in ADHD cases, improved treatment methods, expansion in health insurance coverage, and advancements in healthcare infrastructure.

The market for therapeutics treating attention deficit hyperactivity disorder (ADHD) is shaped to experience significant growth in the upcoming years. The market size is projected to reach “$17 billion by 2029, with a 5.0% compound annual growth rate (CAGR). The anticipated growth is linked to advancements in genetic research and individualized medicine, increased awareness of mental health issues, mental health campaigns at both global and national levels, the proliferation of telehealth, and the incorporation of behavioral therapies. The forecasting period will also be marked by innovative treatment technologies, concerted research and development efforts, incorporation of digital therapeutics, strategies based on precision medicine, and progression in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

What Forces Are Driving The Growth Of The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The upward trend in attention-deficit hyperactivity disorder (ADHD) cases is anticipated to fuel the development of the ADHD therapeutics market. The surge in ADHD cases denotes an increase in the number of diagnosed patients over time. ADHD treatment strategies focus on addressing the multifaceted aspects of this neurodevelopmental disorder, with the goal of enhancing symptom control, minimizing functional impairment, and enriching the lives of those with ADHD. For example, in a report released by the US-based publishing company, the Guardian, in January 2023, it was estimated that about 170,000 known patients were receiving treatment for ADHD in 2022, marking a 20.4% growth from the 141,000 known patients in the same period in 2021. Thus, the escalating occurrence of ADHD is propelling the expansion of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.

The attention deficit hyperactivity disorder (adhd) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

What Are The Leading Trends And Opportunities In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Sector?

Leading businesses in the ADHD therapeutics market have set their sights on creating and advancing digital technologies such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD in response to the growing need for digital solutions and remote healthcare services. Digital therapeutics entails using top-tier software programs to create evidence-based therapeutic methods aimed at preventing, managing, or treating various medical diseases or disorders. These methods can be used alone or in conjunction with traditional medical treatments. For instance, Akili, a digital health company based in the United States, introduced an over-the-counter (OTC) model of its digital therapeutic video game for adults living with ADHD in June 2023. Their OTC version, known as EndeavorOTC aims to enhance attention span, time management, and organization skills. This move distinguished itself following Akili’s FDA-authorised prescription video game treatment, EndeavorRx, intended for children diagnosed with ADHD. EndeavorOTC offers adults a non-pharmacological alternative for managing ADHD symptoms.

Which Companies Currently Dominate The Competitive Landscape In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

Which Geographic Regions Are Driving Demand In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for therapeutics in attention deficit hyperactivity disorder (adhd) has seen a robust growth in the past few years. It is set to expand from $13.21 billion in 2024 to hit $13.97 billion in 2025, marking a compound annual growth rate (CAGR) of 5.7%. The historical growth in this field is due to factors like increased awareness and diagnostic screenings, a rising number of ADHD cases, advancements in treatment methods, development in healthcare infrastructure, and the broadening of health insurance coverage.

In the coming years, the market for therapeutics in attention deficit hyperactivity disorder (ADHD) is forecasted to experience significant expansion, reaching a valuation of $17 billion in 2029, flaunting a compound annual growth rate (CAGR) of 5.0%. This projected growth in the specified period can be credited to factors such as genetic research and personalized medicine, a rise in mental health consciousness, mental health drives on a global and national level, the growth of telehealth, and the incorporation of behavioral therapies. The prediction period is also likely to witness an array of trends like advancements in treatment technology, research and development efforts, inclusion of digital therapeutics, adoption of precision medicine techniques and novel developments in drug delivery systems.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

What Are the Core Market Drivers Propelling Growth in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

The growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market is anticipated to be fueled by the escalating incidence of ADHD. The surging incidence refers to a rising number of people diagnosed with this neurodevelopmental disorder. ADHD therapeutics are designed to address the complex nature of the disorder with the goal to enhance symptom control, functional disability, quality of life, and general well-being for those living with ADHD. For example, as reported by the Guardian, a US-based news publisher, in January 2023, around 170,000 identified patients were recommended ADHD therapeutics in 2022, marking a 20.4% surge from the 141,000 diagnosed patients in the same span in 2021. Thus, the escalating incidence of ADHD is boosting the growth of the ADHD therapeutic market.

How Is the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segmented?

The attention deficit hyperactivity disorder (adhd) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

Which Regions Are Driving the Next Phase of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

Key players in the ADHD therapeutics market are increasingly putting their attention towards the creation of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD. This move is due to the escalating demand for digital solutions and a surge in the need for remote healthcare. Digital therapeutics are evidence-based treatments propelled by high-grade software that aim to prevent, manage, or cure medical disorders or diseases. These treatments can be used standalone or with conventional medical methods. For example, in June 2023, Akili, an American digital health firm, unveiled an over-the-counter (OTC) version of its videogame-centered digital therapy for adults with ADHD named EndeavorOTC. This OTC version aims to enhance attention, time managing, and organizing skills in adults. This followed the positive outcome from Akili’s FDA-approved prescription video game treatment, EndeavorRx, for children with ADHD. The OTC alternative offers adults a non-drug method to control their ADHD symptoms.

View the full report here:

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

How Is the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Defined and What Are Its Core Parameters?

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Grown from 2024 to 2025?

The market size for therapeutics treating attention deficit hyperactivity disorder (ADHD) has seen robust growth in the past few years. A rise from $13.21 billion in 2024 to $14.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.7% is predicted. The previous growth can be credited to factors such as increased awareness and screening procedures for diagnosis, a growing number of ADHD cases, progress in treatment methods, the evolution of healthcare infrastructure, and the broadening of health insurance coverage.

What Growth Rate Is Anticipated for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market in the Coming Years?

The market size for therapeutics related to attention deficit hyperactivity disorder (ADHD) is forecasted to experience substantial growth in the coming years. By 2029, it is projected to reach $17.25 billion with a compound annual growth rate (CAGR) of 5.2%. The expected growth over the forecast period can be linked to advancements in genetic research and personalized medicine, rising awareness about mental health, international and national mental health campaigns, development of telehealth, and incorporation of behavioral therapies. The key trends during this forecast period comprise of technological enhancements in treatment, research and development efforts, incorporation of digital therapeutics, precision medicine strategies, and drug delivery system innovations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

Who Are the Leading Companies in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

What Are the Key Drivers of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The escalating occurrence of attention-deficit hyperactivity disorder is predicted to foster expansion of the ADHD therapeutics market in the future. This surge in ADHD occurrence alludes to an ascending count of people being diagnosed with this neurodevelopmental disorder over time. Therapies for ADHD strive to address the diverse aspects of this condition, focusing on improved management of symptoms, functional disability, life quality, and overall well-being for those afflicted with ADHD. For instance, the Guardian, a US-based news company reported in January 2023 that an estimated 170,000 recognized patients were prescribed ADHD treatment in 2022, marking a 20.4% growth from the 141,000 recognized patients during the equivalent period in 2021. Thus, the burgeoning prevalence of ADHD is contributing to the advancement of the ADHD therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

What Are the Key Market Segments in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

What Are the Latest Trends in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Leading businesses in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing their efforts on creating digital enhancements such as Endeavor over-the-counter (OTC) versions of digital treatments for ADHD. This is in response to the growing demand for digital solutions as well as an increase in remote healthcare needs. Digital treatments, backed by evidence, use high-quality software programs to prevent, manage or cure a medical disorder. These treatments are developed to be utilized alone or alongside conventional medical treatments. For example, Akili, a digital health company from the US, launched an OTC version of its video game-based digital therapeutic for adults with ADHD in June 2023. Named EndeavorOTC, it was created to improve attention, time management, and organizational skills. This is a follow-up to Akili’s successful FDA-authorized prescription video game treatment, the EndeavorRx, for children with ADHD. The EndeavorOTC provides a non-pharmaceutical treatment option for adults battling ADHD symptoms.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

What Are the Key Regional Markets in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

This Report Delivers Insight On:

1. How big is the attention deficit hyperactivity disorder (adhd) therapeutics market, and how is it changing globally?

2. Who are the major companies in the attention deficit hyperactivity disorder (adhd) therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the attention deficit hyperactivity disorder (adhd) therapeutics market right now?

4. Which products or customer segments are growing the most in the attention deficit hyperactivity disorder (adhd) therapeutics market?

5. What factors are helping or slowing down the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Grown from 2024 to 2025?

The market size for therapeutics treating attention deficit hyperactivity disorder (ADHD) has seen robust growth in the past few years. A rise from $13.21 billion in 2024 to $14.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.7% is predicted. The previous growth can be credited to factors such as increased awareness and screening procedures for diagnosis, a growing number of ADHD cases, progress in treatment methods, the evolution of healthcare infrastructure, and the broadening of health insurance coverage.

What Growth Rate Is Anticipated for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market in the Coming Years?

The market size for therapeutics related to attention deficit hyperactivity disorder (ADHD) is forecasted to experience substantial growth in the coming years. By 2029, it is projected to reach $17.25 billion with a compound annual growth rate (CAGR) of 5.2%. The expected growth over the forecast period can be linked to advancements in genetic research and personalized medicine, rising awareness about mental health, international and national mental health campaigns, development of telehealth, and incorporation of behavioral therapies. The key trends during this forecast period comprise of technological enhancements in treatment, research and development efforts, incorporation of digital therapeutics, precision medicine strategies, and drug delivery system innovations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

Who Are the Leading Companies in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

What Are the Key Drivers of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The escalating occurrence of attention-deficit hyperactivity disorder is predicted to foster expansion of the ADHD therapeutics market in the future. This surge in ADHD occurrence alludes to an ascending count of people being diagnosed with this neurodevelopmental disorder over time. Therapies for ADHD strive to address the diverse aspects of this condition, focusing on improved management of symptoms, functional disability, life quality, and overall well-being for those afflicted with ADHD. For instance, the Guardian, a US-based news company reported in January 2023 that an estimated 170,000 recognized patients were prescribed ADHD treatment in 2022, marking a 20.4% growth from the 141,000 recognized patients during the equivalent period in 2021. Thus, the burgeoning prevalence of ADHD is contributing to the advancement of the ADHD therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

What Are the Key Market Segments in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

What Are the Latest Trends in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Leading businesses in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing their efforts on creating digital enhancements such as Endeavor over-the-counter (OTC) versions of digital treatments for ADHD. This is in response to the growing demand for digital solutions as well as an increase in remote healthcare needs. Digital treatments, backed by evidence, use high-quality software programs to prevent, manage or cure a medical disorder. These treatments are developed to be utilized alone or alongside conventional medical treatments. For example, Akili, a digital health company from the US, launched an OTC version of its video game-based digital therapeutic for adults with ADHD in June 2023. Named EndeavorOTC, it was created to improve attention, time management, and organizational skills. This is a follow-up to Akili’s successful FDA-authorized prescription video game treatment, the EndeavorRx, for children with ADHD. The EndeavorOTC provides a non-pharmaceutical treatment option for adults battling ADHD symptoms.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

What Are the Key Regional Markets in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

This Report Delivers Insight On:

1. How big is the attention deficit hyperactivity disorder (adhd) therapeutics market, and how is it changing globally?

2. Who are the major companies in the attention deficit hyperactivity disorder (adhd) therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the attention deficit hyperactivity disorder (adhd) therapeutics market right now?

4. Which products or customer segments are growing the most in the attention deficit hyperactivity disorder (adhd) therapeutics market?

5. What factors are helping or slowing down the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

The growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market is predicted to be spurred by the increasing occurrence of ADHD. The escalating frequency of ADHD is indicative of a rise in the number of cases diagnosed with this neurodevelopmental disorder. ADHD therapeutics aim to cater to the complex nature of the disorder, focusing on symptom management and enhancement of functional disability, quality of life, and overall well-being of those affected by ADHD. To illustrate, Guardian reports reveal that in January 2023, around 170,000 diagnosed patients received prescription for ADHD in 2022, marking a 20.4% rise from the 141,000 identified cases in the corresponding period in 2021. Thus, the expanding prevalence of ADHD contributes to the growth of the ADHD therapeutic market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

How Has the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The ADHD (Attention Deficit Hyperactivity Disorder) therapeutics sector has observed impressive expansion in the past few years. In terms of market size, it’s projected to elevate from $13.21 billion in 2024 to hit $14.1 billion in 2025, with the Compound Annual Growth Rate (CAGR) of 6.7%. The substantial growth during the historic phase is credited to factors such as heightened awareness of diagnosis and screening plans, an increase in ADHD instances, developments in treatment methods, enhancement in healthcare infrastructure, and a wider reach of health insurance coverage.

The market for therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) is projected to experience a robust expansion in the upcoming years, with the market value predicted to reach $17.25 billion by 2029. This represents a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period can be linked to various factors like advancements in genetic research and personalized medicine, a heightened global awareness of mental health, the launch of mental health campaigns at the global and national levels, the proliferation of telehealth, and the incorporation of behavioral therapies. Technological breakthroughs in treatment methods, dedication towards research and development, the amalgamation of digital therapeutics, precision medicine tactics, and novel methods in drug delivery systems are all significant trends predicted for this forecast period.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

What New Market Trends Are Reshaping the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market and Its Opportunities?

Major players in the therapeutics market for attention-deficit hyperactivity disorder (ADHD) are concentrating their efforts on creating digital innovations. Endeavor’s over-the-counter (OTC) versions of digital therapeutics for ADHD are in response to a growing demand for digital solutions and remote healthcare. Digital therapeutics are evidence-based interventions supported by premium software programs to manage, prevent, or cure medical conditions. They are crafted to function independently or augment conventional medical treatments. For instance, Akili, a US digital health firm, in June 2023, introduced an OTC version of its video game-based digital therapeutic for adults with ADHD, called EndeavorOTC. This is aimed to boost attention, time control, and organizational abilities. Furthermore, this development was spurred by the triumph of Akili’s FDA-approved video game therapy, EndeavorRx, for children with ADHD. The OTC version gifts adults a non-pharmaceutical alternative for managing ADHD symptoms.

Who Are the Leading Market Players Fueling Growth in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trend?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

How is the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segemented?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

Which Geographics are Influencing the Growth of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2025, By The Business Research Company:

Augmented Reality In Travel And Tourism Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-in-travel-and-tourism-global-market-report

Virtual Reality Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/virtual-reality-devices-global-market-report

Augmented Reality Software Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-software-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the attention deficit hyperactivity disorder (adhd) therapeutics market grown in recent years?

The market size of therapeutics for attention deficit hyperactivity disorder (ADHD) has seen robust growth in the past few years. The market is projected to expand from $13.21 billion in 2024 to $14.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. Factors contributing to the growth during the historic period include increased awareness and screening programs for diagnosis, an uptick in ADHD incidence rates, improvements in treatment methods, development of healthcare infrastructure, and the broadening of health insurance coverage.

How is the audience analytics market size expected to evolve during the forecast period?

The market for therapeutics related to attention deficit hyperactivity disorder (ADHD) is slated for robust expansion in the coming times. By 2029, it is anticipated to reach a valuation of $17.25 billion, expanding at a compound annual growth rate (CAGR) of 5.2%. Several factors like advancements in genetic research, personalized medicines, growing public awareness about mental health, global and national mental health campaigns, development in telehealth, and inclusion of behavioral therapies are projected as responsible for this growth. The period of prediction also sees major trends like novel technological developments in treatment, drives for research and development, incorporation of digital therapeutics, precision medication strategies, and new innovations in drug distribution systems.

Get your attention deficit hyperactivity disorder (adhd) therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

Which key drivers are propelling the attention deficit hyperactivity disorder (adhd) therapeutics market’s growth?

The surge in the number of attention-deficit hyperactivity disorder (ADHD) cases is likely to accelerate expansion in the ADHD therapeutics market. This escalation refers to the increasing diagnosis of this neurodevelopmental disorder over time. ADHD therapeutics aim to address the complex aspects of the disorder by enhancing symptom management, reducing functional impairment, improving life quality, and bolstering overall well-being for people suffering from ADHD. For example, Guardian, a US-based publishing company, reported in January 2023, that around 170,000 identified patients received ADHD prescriptions in 2022, marking a 20.4% rise from the 141,000 diagnosed patients in the same timeframe in 2021. Therefore such a surge in ADHD threatens the expansion of the ADHD therapeutic market.

What are the market segments in the attention deficit hyperactivity disorder (adhd) therapeutics industry?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

Which leading companies are shaping the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

What key trends are currently impacting the attention deficit hyperactivity disorder (adhd) therapeutics market’s development?

Prominent firms in the ADHD therapeutics market are concentrating on the escalation of digital progression like Endeavor OTC versions of digital therapeutics for ADHD. This is in response to the growing need for digital remedies and remote healthcare services. Digital therapeutics are evidence-supported therapeutical interventions that are powered by top-notch software systems to prevent, control, or cure a medical disorder or disease. These initiatives can function independently or in alignment with conventional medical treatments. For instance, Akili, a digital health enterprise based in the US, unveiled an OTC variant of its videogame-oriented digital therapy for adults dealing with ADHD in June 2023. The OTC edition, named EndeavorOTC, is structured to enhance focus, time administration, and organizational abilities. Moreover, this step comes after the triumph of Akili’s FDA-approved prescription videogame treatment, EndeavorRx, developed for children suffering from ADHD. The OTC version offers adults a non-pharmaceutical treatment option for managing ADHD symptoms.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

Which geographic areas are influencing the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Augmented Reality In Travel And Tourism Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-in-travel-and-tourism-global-market-report

Virtual Reality Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/virtual-reality-devices-global-market-report

Augmented Reality Software Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-software-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Over the Forecast Period of 2025 to 2034?

Recently, a considerable growth has been observed in the market size of therapeutics for attention deficit hyperactivity disorder (ADHD). The market, which was worth $13.21 billion in 2024, is projected to escalate to $14.1 billion in 2025, marking a compound annual growth rate (CAGR) of 6.7%. The previous growth in the market is largely due to factors like improved diagnostic awareness, increased screening programs, a rising rate of ADHD cases, advancements in treatment methods, development in healthcare infrastructure, and the expansion of health insurance coverage.

The market for therapeutics in attention deficit hyperactivity disorder (ADHD) is projected to experience substantial growth in the upcoming years, with an expected valuation of $17.25 billion in 2029, growing at a compounded annual growth rate (CAGR) of 5.2%. This growth in the forecasted period can be linked to advancements in genetic research and personalized medicinal treatments, heightened recognition and understanding of mental health, and the introduction of global and national initiatives towards mental health improvement. The expansion of telehealth capabilities and the incorporation of behavioral therapies also contribute to this growth. Key trends projected for this period involve the introduction of novel technological solutions in treatment, intensified research and development efforts, the use of digital therapeutics, precision medicinal approaches, and the introduction of new drug delivery systems.

What Major Innovations Are Driving the Accelerated Growth of the attention deficit hyperactivity disorder (adhd) therapeutics Market?

Expectations for the attention-deficit hyperactivity disorder (ADHD) therapeutics market to grow are being propelled by an increasing occurrence of ADHD. Such rise in the number of ADHD cases pertains to an expanding group of individuals diagnosed with this neurodevelopmental disorder. The complexity of the condition is handled by ADHD therapeutics, with an aim to boost symptom management, functional impairment, quality of life, amongst others, for those affected by ADHD. For instance, as reported by The Guardian, a US news publisher, in January 2023, about 170,000 identified patients were prescribed for ADHD in the previous year – an increase of 20.4% from the 141,000 identified patients in the same period in 2021. Consequently, the growing occurrence of ADHD is powering the expansion of the ADHD therapeutic market.

Get Your Free Sample of the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are:

• Pfizer Inc._x000D_

• Johnson And Johnson Services Inc._x000D_

• Novartis AG_x000D_

• GlaxoSmithKline plc_x000D_

• Takeda Pharmaceutical’s_x000D_

What Key Trends Are Currently Impacting the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market’s Development?

Key players in the ADHD therapeutics market are concentrating on the introduction of digital innovations like Endeavor OTC versions of digital treatments for ADHD, given the growing demand for digital solutions and remote healthcare. Digital treatments are evidence-based therapeutic strategies empowered by superior software applications used to prevent, cure or manage a medical condition or illness. They can be used either alone or in tandem with conventional medical treatments. For instance, Akili, a digital healthcare firm based in the US, introduced an OTC version of its digital therapeutic video game for adult ADHD patients in June 2023. The OTC variant, named EndeavorOTC, aims to enhance attention, time management, and organizational capabilities. This step follows the success of Akili’s FDA-approved prescription video game therapy, EndeavorRx, meant for children with ADHD. The OTC version offers adults a non-pharmacological option for controlling ADHD symptoms.

Get Instant Access to the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

Which Key Market Segments Comprise the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market and Drive Its Revenue Growth?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –

1) By Drug Type: Stimulants, Non-Stimulants

2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy

3) By Age Group: Pediatric And Adolescent, Adult

4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:

1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants

2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Which Geographical Regions Are Pioneering Growth in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD.

Browse Through More Similar Reports By The Business Research Company:

Augmented Reality In Travel And Tourism Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-in-travel-and-tourism-global-market-report

Virtual Reality Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/virtual-reality-devices-global-market-report

Augmented Reality Software Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/augmented-reality-software-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: